Atopic Dermatitis Clinical Trials in Los Angeles, California

11 studies are recruiting for atopic dermatitis in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

   This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Investigational Site, Los Angeles, California

   Locations

   71 in total

   Run by

   Apogee Therapeutics, Inc.

   See if you can join NCT07003425 on ClinicalTrials.gov

2. A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

   The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. A…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Metropolis Dermatology - DTLA, Los Angeles, California

   Locations

   23 in total

   Run by

   Pfizer

   See if you can join NCT07216027 on ClinicalTrials.gov

3. A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

   This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCLA Division of Dermatology, Los Angeles, California

   Locations

   29 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07223697 on ClinicalTrials.gov

4. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Metropolis Dermatology, Los Angeles, California

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

5. Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

   This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Los Angeles, California

   Locations

   105 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06947993 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

   The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

   Stage

   Phase 2

   Ages

   18 to 74

   Site

   Inmagene Site 23, Los Angeles, California

   Locations

   30 in total

   Run by

   Inmagene LLC

   See if you can join NCT07037901 on ClinicalTrials.gov

7. This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

   The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. …

   Stage

   Not phased

   Ages

   12 and older

   Site

   Dermatology Research Associates - Los Angeles- Site Number : 8400020, Los Angeles, California

   Locations

   79 in total

   Run by

   Sanofi

   See if you can join NCT07290803 on ClinicalTrials.gov

8. A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

   This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive s…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Enveda Investigative Site, Los Angeles, California

   Locations

   9 in total

   Run by

   Enveda Therapeutics

   See if you can join NCT07643766 on ClinicalTrials.gov

9. Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   California Allergy and Asthma Medical Group, Los Angeles, California

   Locations

   16 in total

   Run by

   Oneness Biotech Co., Ltd.

   See if you can join NCT06397911 on ClinicalTrials.gov

10. A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

    The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    California Allergy and Asthma Medical Group, Los Angeles, California

    Locations

    98 in total

    Run by

    Pfizer

    See if you can join NCT05995964 on ClinicalTrials.gov

11. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

    The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

    Stage

    Not phased

    Ages

    12 and older

    Site

    Galderma Investigational Site 7099, Los Angeles, California

    Locations

    108 in total

    Run by

    Galderma R&D

    See if you can join NCT06988605 on ClinicalTrials.gov